CA
NZ
UK
AU
IND
US
UnitedHealth Group (NYSE:UNH) shares edged higher in pre-market trading on Tuesday, tracking broader strength across managed-care and health insurance peers after Centene (NYSE:CNC) reported a strong second-quarter beat with net income surpassing $1 billion and improved health benefits ratios, easing sector-wide concerns about medical …
AbbVie (NYSE:ABBV) shares traded higher in pre-market action on Tuesday after Barclays raised its price target on the stock to $300 from $275 while maintaining an Overweight rating. The upgrade adds to bullish analyst sentiment following the company's recently completed acquisition of Apogee Therapeutics.
Altimmune (NASDAQ:ALT) shares surged in pre-market trading on Tuesday after the company announced positive topline results from its Phase 2 RECLAIM trial evaluating pemvidutide, an investigational balanced glucagon and GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder. The trial …
Capricor Therapeutics Disputes FDA Statistical Methodology
ZEPHYR Trial Meets Primary Schizophrenia Endpoint
Entera Bio Financing Strengthens Clinical Funding Position
Matinas BioPharma Terminates BTIG Equity Facility
Forte Biosciences Acquisition Expands argenx Immunology Strategy
Seralutinib NDA Filing Moves Towards September 2026
MapLight Therapeutics, Inc. (NASDAQ:MPLT) shares collapsed in Monday trading, even as the company characterized topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in schizophrenia as positive. The sharp decline reflects a market interpretation that diverged significantly from the company's own framing of …
Please wait processing your request...